antibody-drug conjugates

In this podcast episode, Samuel Klempner, MD, and Gregory Botta, MD, PhD, provide expert commentary on the rationale and development of novel agents under investigation for targeting claudin 18.2 in gastric and gastroesophageal cancers, with topics including:

• Expression patterns and function of the claudin family of proteins in normal gastric tissues
• Biologic rationale for utility of claudin 18.2 as an actionable therapeutic target in oncology
• Prognostic implications of claudin 18.2 overexpression in gastric and gastroesophageal cancers
• Laboratory methodology involved in claudin 18.2 scoring as a potential predictive biomarker for patient selection
• Future directions for clinical development of agents targeting claudin 18.2, including monoclonal antibodies, bispecific antibodies, antibody‒drug conjugates, and CAR T-cell constructs

Presenters:

Samuel Klempner, MD
Associate Professor
Department of Medicine
Division of Hematology-Oncology
Mass General Cancer Center
Harvard Medical School
Boston, Massachusetts

Gregory Botta, MD, PhD
Clinical Professor of Medicine
Department of Medicine
Division of Hematology & Oncology
University of California San Diego
La Jolla, California

Content for this program was supported by educational grants from Astellas and Bristol Myers Squibb.

Link to the full program, including a CME-certified text module, downloadable slideset, and ClinicalThought (coming soon!):
bit.ly/3lQxPrq

In this podcast episode from a live CCO Cancer Conversations webinar, Mark Pegram, MD, and Sara Tolaney, MD, MPH, provide expert perspectives on optimal treatment strategies for patients with triple-negative breast cancer (TNBC), with topics including:

• Current data and strategies for using PD-1/PD-L1 inhibitors in early-stage TNBC 
• Clinical implications of PD-L1 status on therapeutic planning for patients with metastatic TNBC 
• Current data and treatment strategies and the future of antibody–drug conjugates in the management of relapsed/refractory advanced TNBC 
• Treatment implications of the presence of BRCA1/2 mutations and homologous recombination deficiency genes in advanced TNBC
• Role of PARP inhibitors in the treatment of TNBC

Presenters: 

Mark Pegram, MD
Professor 
Medical Oncology
Stanford University
Palo Alto, California

Sara Tolaney, MD, MPH
Associate Professor of Medicine
Division of Breast Oncology
Harvard Medical School
Chief, Division of Breast Oncology
Breast Oncology Program
Dana-Farber Cancer Institute
Boston, Massachusetts

Content based on an online CME/CE/CPE program supported by educational grants from Gilead Sciences, Inc.

Link to full program:
http://bit.ly/3iQzDz5

In this second of two podcasts, discuss the management of advanced urothelial cancer with novel therapies and how to address adverse events, and concludes the episode with a review of audience questions and patient cases. This activity is available for CE/CME credit. Claim your credit at pce.is/GIGU.

Contributors:

Arjun Balar, MD

Rana R. McKay, MD

Terran W. Sims, MSN, ACNP-C, CNN-BC, COCN

Dr Balar: consulting fees: Bristol-Myers Squibb, Incyte, Istari Oncology, Janssen, Pfizer; consulting fees/research support: Immunomedics, Seagen; consulting fees/contracted research/fees for non-CME/CE services: AstraZeneca/Medimmune, Genentech; Merck; consulting fees/contracted research: Immunomedics/Gilead, Nektar, Seagen; consulting/ownership interest: EpiVax Oncology, GT Biopharma.

Dr McKay: consulting fees: AstraZeneca, Bristol-Myers Squibb, Calithera, Caris, Dendreon, Exelixis, Janssen, Merck, Myovant, Novarits, Sanofi, Sorrento Therapeutics; Vividion Therapeutics; consulting fees/contracted research: Bayer, Pfizer, Tempus.

Ms Sims: consulting fees: Coloplast.

In this first of two podcasts, expert faculty review the latest data on the management of advanced urothelial cancer with novel therapies including immune checkpoint inhibitors and antibody-drug conjugates. This activity is available for CE/CME credit. Claim your credit at pce.is/GIGU.

Contributors:

Arjun Balar, MD

Terran W. Sims, MSN, ACNP-C, CNN-BC, COCN

Dr Balar: consulting fees: Bristol-Myers Squibb, Incyte, Istari Oncology, Janssen, Pfizer; consulting fees/research support: Immunomedics, Seagen; consulting fees/contracted research/fees for non-CME/CE services: AstraZeneca/Medimmune, Genentech; Merck; consulting fees/contracted research: Immunomedics/Gilead, Nektar, Seagen; consulting/ownership interest: EpiVax Oncology, GT Biopharma.

Ms Sims: consulting fees: Coloplast.

The Oncology Journal Club - Delivering Oncology News Differently

The Oncology Podcast, brought to you by Oncology News Australia, is proud to present Episode 27 in our series The Oncology Journal Club.

Anna Nowak on CheckMate 743 and DREAM3R, Fractals, Elfstedentocht, DPD genotyping, Antibody–drug Conjugates, Coronary Artery Disease, Dr Glaucomflecken and much more...

This week's episode is in our usual format featuring some amazing papers and of course, it wouldn't be the OJC without a few weird and wonderful updates as well, including Twitter account of the week, the amazing paper of the week, some homework on fractals and much more.

Craig gets us started with a paper on immunotherapy and a fascinating interview with Professor Anna Nowak. Eva our Twitter Poll Queen gives us insight into DPD genotyping, with a consensus statement by the German Society for Hematology and Medical Oncology on testing.

Hans has some fascinating updates for us too, talking us through a paper titled ‘Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition’ and he also explains the famous Elfstedentocht or the ‘Eleven Cities Tour’…

With the usual top quality banter, papers you won’t hear of anywhere else and expert analysis from our Hosts, you are in for another great episode of The Oncology Journal Club!

Full bios and the list of all papers discussed are available on our website.

For the latest oncology news visit www.oncologynews.com.au and for regular oncology updates for healthcare professionals, subscribe for free to get the weekly The Oncology Newsletter.

The Oncology Podcast - An Australian Oncology Perspective

In this episode, Naval G. Daver, MD, discusses promising investigational agents and treatment combinations in clinical trials for patients with newly diagnosed and relapsed/refractory AML, including:

• FLT3 inhibitors crenolanib and quizartinib
• Anti-CD47 antibody magrolimab
• IMGN632, a CD123 antibody–drug conjugate
• Anti-CD70 antibody cusatuzumab
• APR-246, targeting the TP53 mutation

Content is part of an online CME program supported by an educational grant from Daiichi-Sankyo.

Link to full program, including a ClinicalThought commentary:  https://bit.ly/2Y2uCG2